Compare HCTI & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HCTI | VYNE |
|---|---|---|
| Founded | 2020 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.5M | 12.5M |
| IPO Year | 2021 | 2018 |
| Metric | HCTI | VYNE |
|---|---|---|
| Price | $2.29 | $0.36 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 346.9K | ★ 901.2K |
| Earning Date | 11-13-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $12,942,000.00 | $524,000.00 |
| Revenue This Year | $47.01 | N/A |
| Revenue Next Year | $44.88 | $16.67 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 6.29 |
| 52 Week Low | $1.37 | $0.28 |
| 52 Week High | $435.75 | $4.30 |
| Indicator | HCTI | VYNE |
|---|---|---|
| Relative Strength Index (RSI) | 48.05 | 45.15 |
| Support Level | $2.17 | $0.36 |
| Resistance Level | $2.54 | $0.42 |
| Average True Range (ATR) | 0.23 | 0.03 |
| MACD | 0.04 | -0.00 |
| Stochastic Oscillator | 52.94 | 9.68 |
Healthcare Triangle Inc is a healthcare information technology company focused on advancing industry-transforming solutions in the sectors of cloud services, data science, and professional and managed services for the healthcare and life sciences industry. The company reinforces healthcare progress through technology and extensive industry know-how. HTI supports healthcare providers and payors, hospitals, and Pharma Life Sciences organizations in their effort to improve health outcomes by enabling the adoption of new technologies, data enlightenment, business agility, and accelerated response to immediate business needs and competitive threats. It provides services under three operating segments: Software Services, Managed Services, and Support and Platform Services.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.